Director/PDMR Shareholding
August 22, 2017 - Shire plc (LSE: SHP, NASDAQ: SHPG)
Notification of transaction by person discharging managerial responsibilities
| 1. | Details of the person discharging managerial responsibilities ("PDMR") / person closely associated them ("PCA") | ||
| a) | Name | Flemming Ornskov | |
| 2. | Reason for the notification | ||
| a) | Position / status | Chief Executive Officer - PDMR | |
| b) | Initial notification / amendment | Initial notification | |
| 3. | Details of the issuer, emission allowance participant, auction platform, auctioneer or auction monitor | ||
| a) | Name | Shire plc | |
| b) | LEI | 54930005LQRLI2UXRQ59 | |
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument, type of instrument | Shire plc Ordinary Shares of 5 pence each ("Ordinary Shares") | |
| Identification code | ISIN: JE00B2QKY057 | ||
| b) | Nature of the transaction | Acquisition of Ordinary Shares | |
| c) | Price(s) and volume(s) | Price(s) | Volume(s) |
| £36.6493 | 8,400 | ||
| d) | Aggregated information - Aggregated volume - Price | N/A (single transaction) | |
| e) | Date of the transaction | August 22, 2017 | |
| f) | Place of the transaction | London Stock Exchange | |
Oliver Strawbridge
Senior Assistant Company Secretary
For further information please contact:
| Investor Relations | ||
| Ian Karp | [email protected] | +1 781 482 9018 |
| Robert Coates | [email protected] | +44 1256 894874 |
| Media | ||
| Lisa Adler | [email protected] | +1 617 588 8607 |
| Debbi Ford | [email protected] | +1 617 949 9083 |
NOTES TO EDITORS
About Shire
Shire is the leading global biotechnology company focused on serving people with rare diseases. We strive to develop best-in-class products, many of which are available in more than 100 countries, across core therapeutic areas including Hematology, Immunology, Neuroscience, Ophthalmics, Lysosomal Storage Disorders, Gastrointestinal / Internal Medicine / Endocrine and Hereditary Angioedema; and a growing franchise in Oncology.
Our employees come to work every day with a shared mission: to develop and deliver breakthrough therapies for the hundreds of millions of people in the world affected by rare diseases and other high-need conditions, and who lack effective therapies to live their lives to the fullest.


BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG
OpenAI Addresses Security Vulnerability in macOS App Certification Process
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts
Pony.ai, Uber, and Verne Launch Europe's First Commercial Robotaxi Service in Zagreb
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth
Tokyo Electric Power Attracts Major Investors Amid Billion-Dollar Restructuring Push
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts
SanDisk Joins Nasdaq-100, Replacing Atlassian on April 20
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market
Anthropic's Mythos AI Model Sparks Emergency Cybersecurity Meeting With Top U.S. Bank CEOs
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts
Bill Ackman Eyes New Fund to Bet Against Market Complacency
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs 



